Cargando…

The diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: COVID-19 or cytosine arabinoside?

BACKGROUND: Idiopathic intracranial hypertension is a rare neurological condition among children. Its manifestations vary from mild headaches to loss of vision. Although rare, COVID-19 infection and high dose cytosine arabinoside have been reported as risk factors for this neurological disorder. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakez, Rim, Boufrikha, Wiem, Lakhal, Sana, Boughammoura, Amel, Laatiri, Mohamed Adnene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058734/
https://www.ncbi.nlm.nih.gov/pubmed/35501718
http://dx.doi.org/10.1186/s12883-022-02689-z
_version_ 1784698174964760576
author Rakez, Rim
Boufrikha, Wiem
Lakhal, Sana
Boughammoura, Amel
Laatiri, Mohamed Adnene
author_facet Rakez, Rim
Boufrikha, Wiem
Lakhal, Sana
Boughammoura, Amel
Laatiri, Mohamed Adnene
author_sort Rakez, Rim
collection PubMed
description BACKGROUND: Idiopathic intracranial hypertension is a rare neurological condition among children. Its manifestations vary from mild headaches to loss of vision. Although rare, COVID-19 infection and high dose cytosine arabinoside have been reported as risk factors for this neurological disorder. In patients with acute leukemia, idiopathic intracranial hypertension diagnosis is simple, but finding its etiology can be difficult. CASE PRESENTATION: We report a case of a 9-year-old boy with an ongoing treatment for T-acute lymphoblastic leukemia presenting with persistent headaches and diplopia. A diagnosis of idiopathic intracranial hypertension was retained based on clinical, imaging and laboratory findings. Due to its rarity, we describe its clinical and therapeutic features and highlight the challenging etiological dilemma between COVID-19 infection and high dose cytosine arabinoside administration. CONCLUSION: Persistent headache in a pediatric patient with leukemia can be due to many neurological disorders other than leukemic relapse. Given the improvement of the neurological symptoms after the SARS-CoV-2 PCR negativization and the successful re-introduction of high dose cytosine Arabinoside, the diagnosis of idiopathic intracranial hypertension associated with Covid-19 infection was withheld. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-022-02689-z.
format Online
Article
Text
id pubmed-9058734
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90587342022-05-02 The diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: COVID-19 or cytosine arabinoside? Rakez, Rim Boufrikha, Wiem Lakhal, Sana Boughammoura, Amel Laatiri, Mohamed Adnene BMC Neurol Case Report BACKGROUND: Idiopathic intracranial hypertension is a rare neurological condition among children. Its manifestations vary from mild headaches to loss of vision. Although rare, COVID-19 infection and high dose cytosine arabinoside have been reported as risk factors for this neurological disorder. In patients with acute leukemia, idiopathic intracranial hypertension diagnosis is simple, but finding its etiology can be difficult. CASE PRESENTATION: We report a case of a 9-year-old boy with an ongoing treatment for T-acute lymphoblastic leukemia presenting with persistent headaches and diplopia. A diagnosis of idiopathic intracranial hypertension was retained based on clinical, imaging and laboratory findings. Due to its rarity, we describe its clinical and therapeutic features and highlight the challenging etiological dilemma between COVID-19 infection and high dose cytosine arabinoside administration. CONCLUSION: Persistent headache in a pediatric patient with leukemia can be due to many neurological disorders other than leukemic relapse. Given the improvement of the neurological symptoms after the SARS-CoV-2 PCR negativization and the successful re-introduction of high dose cytosine Arabinoside, the diagnosis of idiopathic intracranial hypertension associated with Covid-19 infection was withheld. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-022-02689-z. BioMed Central 2022-05-02 /pmc/articles/PMC9058734/ /pubmed/35501718 http://dx.doi.org/10.1186/s12883-022-02689-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Rakez, Rim
Boufrikha, Wiem
Lakhal, Sana
Boughammoura, Amel
Laatiri, Mohamed Adnene
The diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: COVID-19 or cytosine arabinoside?
title The diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: COVID-19 or cytosine arabinoside?
title_full The diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: COVID-19 or cytosine arabinoside?
title_fullStr The diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: COVID-19 or cytosine arabinoside?
title_full_unstemmed The diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: COVID-19 or cytosine arabinoside?
title_short The diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: COVID-19 or cytosine arabinoside?
title_sort diagnostic dilemma of idiopathic intracranial hypertension in a child with acute lymphoblastic leukemia: covid-19 or cytosine arabinoside?
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058734/
https://www.ncbi.nlm.nih.gov/pubmed/35501718
http://dx.doi.org/10.1186/s12883-022-02689-z
work_keys_str_mv AT rakezrim thediagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT boufrikhawiem thediagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT lakhalsana thediagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT boughammouraamel thediagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT laatirimohamedadnene thediagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT rakezrim diagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT boufrikhawiem diagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT lakhalsana diagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT boughammouraamel diagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside
AT laatirimohamedadnene diagnosticdilemmaofidiopathicintracranialhypertensioninachildwithacutelymphoblasticleukemiacovid19orcytosinearabinoside